Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant MelanomaMark R. Middleton, N. Thatcher, Jean‐Jacques Grob et al.|Journal of Clinical Oncology|2000Cited by 1.3k
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humansIan D. Davis, Jonathan Cebon, Andrew M. Scott et al.|Proceedings of the National Academy of Sciences|2004Cited by 440
Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.Georgina V. Long, F. Stephen Hodi, Reinhard Dummer et al.|Journal of Clinical Oncology|2016Cited by 110
Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβLaura J. Vella, Jonathan Cebon|Neoplasia|2017Cited by 66
Stem Cell Media Culture of Melanoma Results in the Induction of a Nonrepresentative Neural Expression ProfileMatthew Anaka, Jonathan Cebon|Stem Cells|2011Cited by 15